a minute agoFrance begins testing vaccine in September
Periskopi(6 years ago)
(6 years ago)pharmaceutical company F RENCH Sanofi SA aims to include thousands of volunteers for testing an experimental vaccine of the Coronavirus that is developing with GlaxonSmithKline Pl. Sanofi is developing two possible vaccines to prevent COVID 19, a disease caused by the new coronary, and it is reportedly exploring several options for production [...]
pharmaceutical company F RENCH Sanofi SA aims to include thousands of volunteers for testing an experimental vaccine of the Coronavirus that is developing with GlaxonSmithKline Pl.
Sanofi is developing two possible vaccines to prevent COVID 19, a disease caused by the new choreography, and is reportedly exploring several options for its production.
Of the more than 100 potential vaccines being developed, ten have so far entered the clinical testing phase, California-based Milken Institute reported.
Sanofi, whose department will have experience in flu vaccines, in co-operation with British company GlaxonSmithKline (GSK), has identified candidates for the vaccine he hopes will be ready next year.
Sanofi will provide an antigen protein a molecule that increases the body's immune response based on the platform used to produce flu vaccine flu, while the GSK will provide one of its proven aides that strengthen the body's immune response to create more antibodies and create longer immunity, Kosovo Press broadcasts.
The first test of the vaccine, which would include hundreds, will begin in September, Sanofi hopes.
Sanofi is also working with US-based Translate Bio Inc to develop another vaccine based on m technology The RNA, similar to experimental vaccines developed by Pfizer Inc. in partnership with BioNTech SE.
